---

$10.51

+0.3010 ( +1.65% ) 32.1K

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Analyst Insights

---

You need to login to view this content.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-08-13	Sale	-5017.00	Rodman David Malcom
2024-07-26	Sale	-550000.00	Slingsby Brian Taylor
2024-07-18	Sale	-525.00	Rodman David Malcom
2024-07-12	Sale	-5017.00	Rodman David Malcom
2024-07-12	Sale	-15746.00	Congleton Jon
2024-07-12	Sale	-10757.00	Levy Adam Scott
2024-06-20	Sale	-17766.00	Congleton Jon
2024-06-17	Sale	-44000.00	Gold Alexander M
2024-06-14	Sale	-16607.00	Congleton Jon
2024-06-13	Sale	-5017.00	Rodman David Malcom

Reset

Symbol	Issuer Name	Market Value ↓	Share Quantity
No records found.